Decreased immunosuppressive effect of cortisol on natural killer cytotoxic activity in senile dementia of the Alzheimer type

Dementia and Geriatric Cognitive Disorders

Volumn 9, Issue 3, 1998, Pages 149-156

  Solerte, Sebastiano Bruno ^a   Cerutti, Nadia ^a   Severgnini, Silvia ^a   Rondanelli, Mariangela ^a   Ferrari, Ettore ^a   Fioravanti, Marisa ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Alzheimer's disease; Cortisol; Interleukin 2; Natural killer cell

Indexed keywords

CYTOKINE; GLUCOCORTICOID; HYDROCORTISONE; INTERLEUKIN 2;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIINFARCT DEMENTIA; NATURAL KILLER CELL; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; CYTOTOXICITY, IMMUNOLOGIC; DEMENTIA, MULTI-INFARCT; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; KILLER CELLS, NATURAL; MALE; REFERENCE VALUES;

EID: 0031944880     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000017040     Document Type: Article

References (54)

1. Ishii T, Haga S: Identification of components of immunoglobulins in senile plaques by means of fluorescent technique. Acta Neuropathol 1975;32:157-162.
2. Miller AE, Neighbour PA, Katzman R, Aronson M, Lipkowitz R: Immunological studies in senile dementia of the Alzheimer type: Evidence for enhanced suppressor cell activity. Ann Neurol 1981;10:506-510.
3. Rogers J, Luber-Narod J, Styren SD, Civin WH: Expression of immune system associated antigens by cells of the human central nervous system: Relationship to the pathology of Alzheimer's disease. Neurobiol Aging 1988;9:339-349.
4. Gautrin D, Gauthier S: Alzheimer's disease: Environmental factors and etiologic hypothesis. Can J Neurol Sci 1989;16:375-387.
5. Ikeda T, Yamamoto K, Takahashi K, Kaneyuki H, Yamada M: Interleukin-2 receptor in peripheral blood lymphocytes of Alzheimer's disease patients. Acta Psychiatr Scand 1991;84:262-265.
6. Huberman M, Shalit F, Roth-Deri I, Gutman B, Brodie C, Kott E, Sredini B: Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage. J Neuroimmunol 1994;52:147-152.
7. McGeer PL, Rogers J, McGeer EG: Neuroimmune mechanisms in Alzheimer's disease pathogenesis. Alzheimer Dis Assoc Disord 1994;8:149-158.
8. Solerte SB, Fioravanti M, Severgnini S, Locatelli M, Renzullo M, Pezza N, Cerutti N, Ferrari E: Enhanced cytotoxic response of natural killer cells to interleukin-2 in Alzheimer's disease. Dementia 1996;7:343-348.
9. Solerte SB, Fioravanti M, Severgnini S, Cerutti N, Locatelli M, Terenzi F, Cottinelli M, Pezza N, Ferrari E: Cortisol, Dhea-sulfate (DHEAS) and natural killer (NK) cell function in the clinical characterization of Alzheimer's disease. J Endocrinol Invest 1996;19(suppl 5):52.
10. Solerte SB, Fioravanti M, Pascale A, Ferrari E, Govoni S, Battaini F: Increased natural killer cell cytotoxicity in Alzheimer's disease may involve protein kinase C dysregulation. Neurobiol Aging, in press.
11. Solerte SB, Fioravanti M, Severgnini S, Pezza N, Locatelli M, Cerutti N, Terenzi F, Ferrari E: Excitatory pattern of gamma-interferon on natural killer cell activity in senile dementia of the Alzheimer type. Dement Geriatr Cogn Disord 1997;8:308-313.
12. Parrillo JE, Fauci AS: Comparison of the effector cells in human spontaneous cellular cytotoxicity and antibody-dependent cellular cytotoxicity: Differential sensitivity of effector cells to in vivo and in vitro corticosteroids. Scand J Immunol 1978;8:99-107.
13. Oshimi K, Gonda N, Sumiya M, Kano S: Effects of corticosteroids on natural killer activity in systemic lupus erithematosus. Clin Exp Immunol 1980;40:83-88.
14. Onsrud M, Thorsby E: Influence of in vivo hydrocortisone on some human blood lymphocyte populations. Scand J Immunol 1981;13:573-579.
15. Holbrook NJ, Cox WI, Horner HC: Direct suppression of natural killer activity in human peripheral blood leukocyte cultures by glucocorticoids and its modulation by interferon. Cancer Res 1983;43:4019-4025.
16. Gatti G, Cavallo R, Sartori ML, Marinone C, Angeli A: Cortisol at physiological concentrations and prostaglandin E are additive inhibitors of human natural killer cell activity. Immunopharmacology 1986;11:109-128.
17. Gatti G, Cavallo R, Sartori ML, Del Ponte D, Masera R, Salvadori A, Carignola R, Angeli A: Inhibition by cortisol of human natural killer (NK) cell activity. J Steroid Biochem 1987;26:49-58.
18. 2+-dependent pathways in the inhibition of human natural killer (NK) cell activity by cortisol. Immunopharmacology 1989;18:11-22.
19. Hiserodt JC, Britvan LJ, Targan SR: Characterization of the cytolytic reaction mechanism of the human natural killer lymphocytes: resolution into binding, programming and killer cell-independent step. J Immunol 1982;129:1782-1787.
20. Hiserodt JC, Britvan LJ, Targan SR: Studies on the mechanism of the natural killer cell lethal hit: Analysis of the mechanisms of protease inhibition of the lethal hit. J Immunol 1983;131:2705-2709.
21. Herberman RB, Reynolds CW, Ortaldo JR: Mechanisms of cytotoxicity by natural killer (NK) cells. Annu Rev Immunol 1986;4:651-680.
22. Gillis S, Crabtree GR, Smith KA: Glucocorticoid inhibition of T-cell growth factor production. I. The effect of mitogen induced lymphocyte proliferation. J Immunol 1979;123:1624-1631.
23. Munck A, Guyre PM, Holbrook NJ: Physiologic function of glucocorticoids in stress and their relation to pharmacologic actions. Endocr Rev 1984;5:25-44.
24. Armanini D, Karbowiak I, Scali M, Orlandini E, Zampollo V, Vittadello G: Corticosteroid receptors and lumphocytes subsets in mononuclear leukocytes in aging. Am J Physiol 1992;262:E464-E466.
25. Gurevich D, Siegel B, Dumlao M, Perl E, Chaitin P, Bagne C, Oxenkrug G: HPA axis responsivity to dexamethasone and cognitive impairment in dementia. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:297-308.
26. Linder J, Nolgård P, Näsman B, Bäck O, Uddhammar A, Olsson T: Decreased peripheral glucocorticoid sensitivity in Alzheimer's disease. Gerontology 1993;39:200-206.
27. Ferrari E, Magri F, Dori D, Nescis T, Molla G, Fioravanti M, Solerte SB: Neuroendocrine correlates of the aging brain in humans. Neuroendocrinology 1995;61:464-470.
28. Ferrari E, Magri F, Locatelli M, Balza G, Nescis T, Battegazzore C, Cuzzoni G, Solerte SB: Chrono-neuroendocrine markers of the aging brain. Aging Clin Exp Res 1996;8:320-327.
29. Landfield PW, Eldridge JC: The glucocorticoid hypothesis of brain aging and neurodegeneration: recent modification. Acta Endocrinol 1991;125:54-64.
30. Gottfries CG, Balldin J, Blennow K, Brane G, Karlsson I, Regland B, Wallin A: Regulation of the hypothalamic-pituitary adrenal axis in dementia disorders. Ann NY Acad Sci 1994;746:336-344.
31. Balldin J, Blennow K, Brane G, Gottfries CG, Karlsson I, Regland B, Wallin A: Relationship between mental impairment and HPA axis activity in dementia disorders. Dementia 1994;5:252-256.
32. Ligthart GJ, Corberand JX, Fourmier C, Galanaud P, Hijmans W, Kennes B, Muller-Hermelink HK, Steinmann GG: Admission criteria for immunogerontological studies in man: the SENIEUR protocol. Mech Ageing Dev 1984;28:47-55.
33. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 3 revised. Washington, American Psychiatric Association, 1987.
34. Mckhann G, Drachman D, Folstein M, Katzmann R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Workgroup under the auspices of Department of Healthy and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
35. Hachinski VC, Lassen NA, Marshall J: Multiinfarct dementia: A cause of mental deterioration in the elderly. Lancet 1974;ii:207-210.
36. Weintraub S, Baratz R, Mesulam MM: Daily living activities in the assessment of dementia; in Corkin S, Davis KL, Crowden JH, Usdin E, Wurtmann JJ (eds): Alzheimer's Disease: A Report of Progress in Research. New York, Raven Press, 1982, pp 109-192.
37. Folstein M, Folstein S, McHugh PR: Mini Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 1975;12:189-198.
38. Timonen T, Ranki A, Saksele E, Hayry P: Fractionation, morphological and functional characterization of effector cells responsible for human natural killer activity against cell-line targets. Cell Immunol 1979;48:133-139.
39. Boyum A: Isolation of mononuclear cells and granulocytes from human blood. Scand Clin Lab Invest 1968;21(suppl):31-50.
40. Korzeniewski C, Callewaert DM: An enzyme-release assay for natural cytotoxicity. J Immunol Methods 1983;64:313-320.
41. Pross HF, Baynes MG, Rubin P, Shragge P, Patterson MS: Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantification of natural killer cell activity. J Clin Immunol 1981;1:51-63.
42. Trinchieri G, Santoli D: Enhancement of human natural killer cell activity by interferon. J Immunol 1978;120:1845-1850.
43. Henney CS, Kuribayashi K, Kern DE, Gillis S: Interleukin-2 augments natural killer cells activity. Nature 1981;291:335-337.
44. Robertson MJ, Ritz J: Biology and clinical relevance of human natural killer cells. Blood 1990;76:2421-2438.
45. Fauci AS: Mechanisms of corticosteroid action on lymphocytes subpopulations. I. Redistribution of circulating T and B lymphocytes to the bone marrow. Immunology 1975;28:669-680.
46. Fauci AS: Mechanisms of the immunosuppressive and anti-inflammatory effects of glucocorticoids. J Immunopharmacol 1975;1:1-25.
47. Sei Y, Vitkovic L, Yokoyama MM: Cytokines in the central nervous system: Regulatory roles in neuronal function, cell death and repair. Neuroimmunomodulation 1995;2:121-133.
48. Rupprecht R, Frölich L, Mergenthaler T, Kornhuber J, Wodar ZN, Riederer P, Maurer K: Glucocorticoid receptors on mononuclear leukocytes in Alzheimer's disease. Psychiatry Res 1990;34:237-241.
49. Jacobson L, Sapolsky R: The role of the hippocampus in feed-back regulation of the hypothalamic-pituitary-adrenocortical axis. Endocr Rev 1991;12:118-131.
50. De Leon MJ, George AE, Stylopoulos LA, Smith G, Miller DC: Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet 1989;ii:672-673.
51. McGeer PL, Rogers J: Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 1992;42:447-449.
52. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P, Kogan F; Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-1611.
53. Breitner JCS, Gan BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, Anthony JC: Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study. Neurology 1994;44:227-232.
54. Aisen PS, Marin D, Altstiel L, Goodwin C, Baruch B, Jacobson R, Ryan T, Davis KL: A pilot study of prednisone in Alzheimer's disease. Dementia 1996;7:201-206.